ClinicalTrials.gg
CompletedNCT02815592Updated Sep 4, 2024

Trial of BMS-986012 in Combination With Platinum and Etoposide

A Phase 1 interventional study of BMS-986012 and Cisplatin in Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Enrollment
14th of 17
12 · median 92
Started
2016
with 2 others
Phase 1
6 of 19
none open now
Registered
10th of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2016, is one of 6 in phase 1, and was the 10th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Male and Females 18 years of age or older
  • Pulmonary SCLC documented by histology or cytology
  • Extensive disease (Stage IV) SCLC
  • (ECOG) performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior systemic therapy for lung cancer
  • Symptomatic
  • Grade 2 peripheral neuropathy
  • Active or chronic infection with (HIV), virus (HBV), or virus (HCV
  • Other active or prior malignancy within 2 years

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Experimental Arm 1

    BMS-986012/Cisplatin/Etoposide

    Drug: BMS-986012 · Drug: Cisplatin · Drug: Etoposide

  • Experimental
    Experimental Arm 2

    BMS-986012/Carboplatin/Etoposide

    Drug: BMS-986012 · Drug: Etoposide · Drug: Carboplatin

  • Experimental
    Experimental Arm 3A

    BMS-986012/Platinum/Etoposide

    Drug: BMS-986012 · Drug: Etoposide · Drug: Platinum

  • Active comparator
    Active Comparator Arm 3B

    Platinum/Etoposide

    Drug: Etoposide · Drug: Platinum

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Cycle 1, Day 1 up to approximately 26 months.

  2. Number of participants with serious adverse events (SAEs )

    Time frame: Date of enrollment up to approximately 26 months.

  3. Discontinuations due to AEs

    Time frame: Cycle 1, Day 1 up to approximately 26 months.

  4. Number of participants who died due to AEs

    Time frame: Cycle 1, Day 1 up to approximately 26 months.

  5. Number of participants with laboratory toxicity grade shift from baseline

    Time frame: Cycle 1, Day 1 up to approximately 26 months.

  6. Progression Free Survival

    Time frame: From date of first dose or randomization until date of confirmed disease progression, up to 2 years

Secondary outcomes

  1. Maximum observed serum concentration(Cmax)

    Time frame: Cycle 1 Day 1 up to 60 days after last dose

  2. Time of maximum observed serum concentration(Tmax)

    Time frame: Cycle 1 Day 1 up to 60 days after last dose

  3. Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration(AUC(0-T))

    Time frame: Cycle 1 Day 1 up to 60 days after last dose

  4. Observed serum concentration at the end of a dosing interval(Ctau)

    Time frame: Cycle 1 Day 1 up to 60 days after last dose

  5. Area under the concentration-time curve in 1 dosing interval(AUC(TAU))

    Time frame: Cycle 1 Day 1 up to 60 days after last dose

  6. Characterization of Immunogenicity

    Anti-Drug Antibodies

    Time frame: Cycle 1 Day 1 up to 60 days after last dose

07

Study locations

4 sites
  • Local Institution - 0002
    Barcelona, 08035, Spain
  • Local Institution - 0004
    Madrid, 28041, Spain
  • Local Institution - 0003
    Majadahonda - Madrid, 28222, Spain
  • Local Institution - 0010
    Malaga, 29010, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Dec 2019, 36 months.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 36 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2016
First posted
Jun 28, 2016
StartActual
Nov 28, 2016
Primary completionActual
Dec 15, 2019
CompletionActual
Aug 6, 2024
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02815592
Responsible party
Sponsor
First posted
Jun 28, 2016
Start date
Nov 28, 2016
Primary completion
Dec 15, 2019
Completion
Aug 6, 2024
Last update
Sep 4, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atigotatug · Platinum Compounds

Start the discussion